Cargando…

Immune activation by combination human lymphokine-activated killer and dendritic cell therapy

BACKGROUND: Optimal cellular immunotherapy for cancer should ideally harness both the innate and adaptive arms of the immune response. Lymphokine-activated killer cells (LAKs) can trigger early innate killing of tumour targets, whereas long-term adaptive-specific tumour control requires priming of C...

Descripción completa

Detalles Bibliográficos
Autores principales:	West, E J, Scott, K J, Jennings, V A, Melcher, A A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171008/ https://www.ncbi.nlm.nih.gov/pubmed/21847125 http://dx.doi.org/10.1038/bjc.2011.290

Ejemplares similares

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming
por: Merrick, A, et al.
Publicado: (2005)

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
por: Simpson, G R, et al.
Publicado: (2012)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells
por: Zou, Y, et al.
Publicado: (2014)

Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro
por: Etminan, N, et al.
Publicado: (2011)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
por: Vass, S O, et al.
Publicado: (2009)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Beneficial immune modulatory effects of a specific nutritional combination in a murine model for cancer cachexia
por: Faber, J, et al.
Publicado: (2008)

Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
por: Pinzon-Charry, A, et al.
Publicado: (2007)

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting
por: Cockle, J V, et al.
Publicado: (2015)

Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005)

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer
por: Pridgeon, S W, et al.
Publicado: (2011)

Efficacy of gene therapy-delivered cytosine deaminase is determined by enzymatic activity but not expression
por: Dubois, L, et al.
Publicado: (2007)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
por: Legrier, M-E, et al.
Publicado: (2007)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
por: Hemmerle, T, et al.
Publicado: (2013)

Natural killer and lymphokine activated killer cell functions in Hodgkin's disease.
por: Rajaram, N., et al.
Publicado: (1990)

CD8(+) T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4(+) T cells and dependent on natural killer cells
por: Kabingu, E, et al.
Publicado: (2007)

A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients
por: Lesterhuis, W J, et al.
Publicado: (2010)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.
por: Vaz, F., et al.
Publicado: (1995)

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Immunisation with ‘naïve’ syngeneic dendritic cells protects mice from tumour challenge
por: Grimshaw, M J, et al.
Publicado: (2008)

Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity
por: Gigi, V, et al.
Publicado: (2013)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice
por: van Norren, K, et al.
Publicado: (2009)

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
por: Wang, J, et al.
Publicado: (2012)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Epstein–Barr virus renders the infected natural killer cell line, NKL resistant to doxorubicin-induced apoptosis
por: Isobe, Y, et al.
Publicado: (2008)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy
por: Tan, Q, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o9ibl736qjjp9i05rrlfup5cln